UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 175

Sortiert nach

Novel Antiatherosclerotic Therapies

Arteriosclerosis, thrombosis, and vascular biology, 2019-04, Vol.39 (4), p.538

2019

Volltextzugriff (PDF)

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events

The New England journal of medicine, 2019-02, Vol.380 (8), p.752-762

2019

Volltextzugriff (PDF)

Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis

The American heart journal, 2013-08, Vol.166 (2), p.199-207.e15

2013

Volltextzugriff (PDF)

Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes

The New England journal of medicine, 2015-08, Vol.373 (7), p.610-620

2015

Volltextzugriff (PDF)

Interaction of Impaired Coronary Flow Reserve and Cardiomyocyte Injury on Adverse Cardiovascular Outcomes in Patients Without Overt Coronary Artery Disease

Circulation (New York, N.Y.), 2015-02, Vol.131 (6), p.528-535

2015

Volltextzugriff (PDF)

The Confusing Landscape of Cardiovascular Health Assessment, Promotion, and Prediction

Circulation (New York, N.Y.), 2024-03, Vol.149 (12), p.914

Everett, Brendan M

2024

Volltextzugriff (PDF)

Safety Profile of Subjects Treated to Very Low Low-Density Lipoprotein Cholesterol Levels (<30 mg/dl) With Rosuvastatin 20 mg Daily (from JUPITER)

The American journal of cardiology, 2014-12, Vol.114 (11), p.1682-1689

2014

Volltextzugriff (PDF)

Cardiac troponin as a novel tool for cardiovascular risk prediction in Ambulatory Populations

Trends in cardiovascular medicine, 2017-01, Vol.27 (1), p.41-47

Everett, Brendan M., MD, MPH

2017

Volltextzugriff (PDF)

Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients

Seminars in arthritis and rheumatism, 2019-12, Vol.49 (3), p.389-395

2019

Volltextzugriff (PDF)

Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

Cardiovascular diabetology, 2024-02, Vol.23 (1), p.57-57, Article 57

2024

Volltextzugriff (PDF)

Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

Cardiovascular diabetology, 2024-03, Vol.23 (1), p.103-103, Article 103

2024

Volltextzugriff (PDF)

Residual Inflammatory Risk: A Common and Important Risk Factor for Recurrent Cardiovascular Events

Journal of the American College of Cardiology, 2019-05, Vol.73 (19), p.2410-2412

Everett, Brendan M.

2019

Volltextzugriff (PDF)

Caffeine consumption and incident atrial fibrillation in women

The American journal of clinical nutrition, 2010-09, Vol.92 (3), p.509-514

2010

Volltextzugriff (PDF)

Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure

Circulation (New York, N.Y.), 2019-03, Vol.139 (10), p.1289-1299

2019

Volltextzugriff (PDF)

Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)

European heart journal, 2018-10, Vol.39 (38), p.3499-3507

2018

Volltextzugriff (PDF)

Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial

Journal of the American College of Cardiology, 2020-10, Vol.76 (14), p.1660-1670

2020

Volltextzugriff (PDF)

B-Type Natriuretic Peptides Improve Cardiovascular Disease Risk Prediction in a Cohort of Women

Journal of the American College of Cardiology, 2014-10, Vol.64 (17), p.1789-1797

2014

Volltextzugriff (PDF)

Sex Differences in Cardiac Troponin and the Risk of Death or Major Cardiovascular Events

Journal of the American College of Cardiology, 2016-08, Vol.68 (9), p.978-980

2016

Volltextzugriff (PDF)

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee

Journal of the American College of Cardiology, 2020-09, Vol.76 (9), p.1117

2020

Volltextzugriff (PDF)

Impact of Modifiable Risk Factors on B-type Natriuretic Peptide and Cardiac Troponin T Concentrations

The American journal of cardiology, 2016-02, Vol.117 (3), p.376-381

2016

Volltextzugriff (PDF)

Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease

Journal of the American College of Cardiology, 2018-05, Vol.71 (21), p.2405-2414

2018

Volltextzugriff (PDF)

Usefulness of B-type Natriuretic Peptides to Predict Cardiovascular Events in Women (from the Women's Health Study)

The American journal of cardiology, 2015-08, Vol.116 (4), p.532-537

2015

Volltextzugriff (PDF)

Reducing LDL with PCSK9 Inhibitors — The Clinical Benefit of Lipid Drugs

The New England journal of medicine, 2015-10, Vol.373 (17), p.1588-1591

2015

Volltextzugriff (PDF)

2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways

Journal of the American College of Cardiology, 2018-12, Vol.72 (24), p.3200-3223

2018

Volltextzugriff (PDF)

Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study

The American heart journal, 2018-12, Vol.206, p.80-93

2018

Volltextzugriff (PDF)

1 – 25 von 175

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(170)
Mit Volltextzugriff
(156)

Publikationsform

Artikel
(175)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Novel Antiatherosclerotic Therapies

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events

Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis

Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes

Interaction of Impaired Coronary Flow Reserve and Cardiomyocyte Injury on Adverse Cardiovascular Outcomes in Patients Without Overt Coronary Artery Disease

The Confusing Landscape of Cardiovascular Health Assessment, Promotion, and Prediction

Safety Profile of Subjects Treated to Very Low Low-Density Lipoprotein Cholesterol Levels (<30 mg/dl) With Rosuvastatin 20 mg Daily (from JUPITER)

Cardiac troponin as a novel tool for cardiovascular risk prediction in Ambulatory Populations

Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients

Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

Residual Inflammatory Risk: A Common and Important Risk Factor for Recurrent Cardiovascular Events

Caffeine consumption and incident atrial fibrillation in women

Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure

Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)

Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial

B-Type Natriuretic Peptides Improve Cardiovascular Disease Risk Prediction in a Cohort of Women

Sex Differences in Cardiac Troponin and the Risk of Death or Major Cardiovascular Events

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee

Impact of Modifiable Risk Factors on B-type Natriuretic Peptide and Cardiac Troponin T Concentrations

Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease

Usefulness of B-type Natriuretic Peptides to Predict Cardiovascular Events in Women (from the Women's Health Study)

Reducing LDL with PCSK9 Inhibitors — The Clinical Benefit of Lipid Drugs

2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways

Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study

Suchergebnisse filtern